Merck Still Plans Big Cost Savings This Year From Schering-Plough Deal
In his first public appearance since completing the acquisition last November of Schering-Plough, Merck chief executive Richard Clark told an investor conference that roughly half of the projected savings from the merger can be realized this year
You may also be interested in...
SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.
However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011